Summit Therapeutics (NASDAQ:SMMT) Shares Break Above 200 Day Moving Average - Here's What Happened

Key Points

• Summit Therapeutics shares broke above their 200-day moving average, reaching $16.55 before closing at $16.20, up 2.7% with more than 4.4 million shares traded.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $28.61; Goldman Sachs set a $41 target and several firms reiterated buy or outperform ratings.
• Institutional investors, including BlackRock and Bank of America, recently acquired stakes, though institutions collectively own only 4.61% of the company. Summit’s lead oncology candidate is ivonescimab, being developed for non-small cell lung cancer.

Summit Therapeutics PLC (NASDAQ:SMMT - Get Free Report)'s share price passed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $16.19 and traded as high as $16.55. Summit Therapeutics shares last traded at $16.20, with a volume of 4,403,350 shares trading hands.

Wall Street Analysts Forecast Growth

SMMT has been the topic of several recent research reports. Citigroup reaffirmed a "market outperform" rating on shares of Summit Therapeutics in a research note on Tuesday. Morgan Stanley lowered shares of Summit Therapeutics to an "outperform" rating in a research note on Tuesday, September 29th. The Goldman Sachs Group set a $41.00 target price on shares of Summit Therapeutics and gave the stock a "buy" rating in a report on Tuesday, September 29th. Stifel Nicolaus decreased their price target on shares of Summit Therapeutics from $45.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, July 24th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Summit Therapeutics in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $28.61.

Summit Therapeutics Trading Up 2.7%

The firm's fifty day moving average price is $15.98 and its 200 day moving average price is $16.19. The firm has a market capitalization of $12.96 billion, a PE ratio of -14.46 and a beta of -1.51.

Hedge Funds Weigh In On Summit Therapeutics

A number of institutional investors have recently modified their holdings of SMMT. BlackRock Inc. acquired a new position in Summit Therapeutics during the 2nd quarter worth $138,838,000. Bank of America Corp DE bought a new stake in Summit Therapeutics during the second quarter valued at about $12,603,000. Simplify Asset Management Inc. acquired a new stake in shares of Summit Therapeutics in the third quarter valued at about $8,626,000. Elmind Capital LP acquired a new stake in shares of Summit Therapeutics in the second quarter valued at about $7,194,957. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Summit Therapeutics in the second quarter valued at about $6,284,000. Institutional investors own 4.61% of the company's stock.

Summit Therapeutics Company Profile

Summit Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of cancer. The company's primary focus is oncology, with an emphasis on therapies designed to improve outcomes for patients with serious diseases.

Summit's lead product candidate is ivonescimab, a bispecific antibody that is designed to combine immune checkpoint inhibition against PD-1 with anti-angiogenic activity targeting VEGF. The company is advancing ivonescimab in clinical studies for non-small cell lung cancer and is evaluating the therapy in combination with other cancer treatments and across additional treatment settings.

Summit holds exclusive rights to develop and commercialize ivonescimab in markets outside China through a licensing and collaboration agreement with Akeso, a China-based biopharmaceutical company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.